These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16617031)

  • 1. Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
    Eshed V; Benbassat CA; Laron Z
    Growth Horm IGF Res; 2006 Apr; 16(2):119-24. PubMed ID: 16617031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
    Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
    Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
    J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.
    Gallego-Rojo FJ; Gonzalez-Calvin JL; Muñoz-Torres M; Mundi JL; Fernandez-Perez R; Rodrigo-Moreno D
    Hepatology; 1998 Sep; 28(3):695-9. PubMed ID: 9731561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
    Atamaz F; Hepguler S; Karasu Z; Kilic M; Tokat Y
    Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration of insulin-like growth factor (IGF)-I in iliac crest bone matrix in premenopausal women with idiopathic osteoporosis.
    Pepene CE; Seck T; Diel I; Minne HW; Ziegler R; Pfeilschifter J
    Exp Clin Endocrinol Diabetes; 2004 Jan; 112(1):38-43. PubMed ID: 14758570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
    Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome.
    Pérez-Castrillón JL; Vega G; Abad L; Sanz-Cantalapiedra A; Gonzalez Sagredo M; de Luis D; Duenas-Laita A
    Ann Nutr Metab; 2008; 53(2):117-21. PubMed ID: 18997459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities.
    Benbassat CA; Eshed V; Kamjin M; Laron Z
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4586-9. PubMed ID: 14557426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.
    Martinó A; Rosa J; Guzmán J; Ramírez M
    P R Health Sci J; 2005 Jun; 24(2):131-5. PubMed ID: 16116930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.